Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement

Hirokazu Ogino(Tokushima University), Saburo Sone(Io Therapeutics (United States)), Hisatsugu Goto(Tokushima University), Tadaaki Yamada(Kyoto Prefectural University of Medicine), Emiko Nakataki(Tokushima University), Anderson J. Ryan(University of Oxford), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Kenji Ikuta(Nagoya City University), Masaki Hanibuchi(Tokushima University), Yasuhiko Nishioka(Tokushima University)
Kanazawa University Repository for Academic Resources (DSpace) (Kanazawa University)
March 1, 2009
Cited by 23

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134
Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer
|Cancer Research|2005|124